Freeman Hospital

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Source

• Not yet recruiting

  Diagnosis of Women With ANOCA

  NCT07802457· Source

• Recruiting

  DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

  NCT07707895· Phase 1/2· Source

• Not yet recruiting

  Exercise Therapy for Women With ANOCA

  NCT07733986· Source

• Not yet recruiting

  Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)

  NCT07682129· Phase 2· Source

• Recruiting

  A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

  NCT07365995· Phase 3· Source

• Recruiting

  DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

  NCT07440290· Phase 2/3· Source

• Recruiting

  A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

  NCT07332481· Phase 3· Source

• Recruiting

  A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  NCT07438496· Phase 3· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

  NCT07221357· Phase 2/3· Source

• Recruiting

  DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.

  NCT05770544· Phase 2/3· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Source

• Recruiting

  A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

  NCT06855771· Phase 2· Source

• Recruiting

  HOPE Against Cancer Recurrence in HCC

  NCT06717919· Phase 4· Source

• Recruiting

  A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44

  NCT07037862· Phase 1/2· Source

• Recruiting

  A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  NCT06943872· Phase 3· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Source

• Recruiting

  Surgical vs Transcatheter Aortic Valve Replacement in YOUNG Patients

  NCT06861361· Source

• Active, not recruiting

  FARAPULSE Workflow Assessment Registry

  NCT06656884· Source

• Recruiting

  A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

  NCT06615479· Phase 3· Source

• Active, not recruiting

  REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure

  NCT06557798· Source

• Recruiting

  DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

  NCT06988475· Phase 2/3· Source

• Recruiting

  Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

  NCT06274801· Phase 3· Source

• Active, not recruiting

  A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients

  NCT06540391· Phase 1· Source

• Active, not recruiting

  Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

  NCT06456346· Phase 3· Source

• Recruiting

  Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  NCT06324357· Phase 1/2· Source

• Recruiting

  Imperial Prostate 9 - ATLAS (Approaches To Long-Term Active Surveillance)

  NCT06280781· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

  NCT06319820· Phase 3· Source

• Recruiting

  Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma

  NCT05655078· Source

• Enrolling by invitation

  ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation

  NCT05932615· Source

• Recruiting

  Comparison of Allegra vs Sapien Transcatheter Aortic Valves in Valve-In-Valve Indication

  NCT06049654· Source

• Recruiting

  DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

  NCT05770037· Phase 2/3· Source

• Recruiting

  A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.

  NCT07630545· Phase 1· Source

• Enrolling by invitation

  Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy

  NCT06066580· Phase 2· Source

• Recruiting

  DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

  NCT05770102· Phase 2/3· Source

• Recruiting

  DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

  NCT05882058· Phase 2· Source

• Recruiting

  Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  NCT06051617· Phase 3· Source

• Active, not recruiting

  Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

  NCT05701358· Source

• Recruiting

  A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With Cirrhosis

  NCT06461208· Phase 3· Source

• Recruiting

  Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

  NCT05714085· Phase 2/3· Source

• Active, not recruiting

  A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer

  NCT05908734· Phase 1/2· Source

• Active, not recruiting

  FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma

  NCT05466799· Phase 2· Source

• Active, not recruiting

  Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients

  NCT05705973· Source

• Recruiting

  RCT of Implantable Defibrillators in Patients With Non Ischemic Cardiomyopathy, Scar and Severe Systolic Heart Failure

  NCT05568069· Source

• Recruiting

  Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

  NCT05727904· Phase 3· Source

• Recruiting

  DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations

  NCT05786716· Phase 2/3· Source

• Recruiting

  DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

  NCT05768178· Phase 2/3· Source

• Recruiting

  DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

  NCT05722886· Phase 2/3· Source

• Recruiting

  ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

  NCT05580562· Phase 3· Source

• Recruiting

  A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

  NCT05611801· Phase 3· Source

Showing 50 of 97.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers12 recruiting
• Lung cancer8 recruiting
• Colorectal cancer7 recruiting
• Melanoma6 recruiting
• Multiple myeloma6 recruiting
• Ovarian cancer5 recruiting
• Prostate cancer5 recruiting
• Aortic stenosis4 recruiting
• Coronary artery disease4 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• Duchenne muscular dystrophy3 recruiting
• Heart failure3 recruiting
• Liver and biliary tract cancer3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Bronchiectasis2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Hodgkin lymphoma2 recruiting
• Lupus (SLE)2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Neuroblastoma2 recruiting
• Neuroendocrine tumours2 recruiting
• Pancreatic cancer2 recruiting
• Thyroid cancer2 recruiting
• Acute myeloid leukaemia1 recruiting
• Bladder cancer1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Endometrial cancer1 recruiting
• Follicular lymphoma1 recruiting
• Haemophilia1 recruiting
• Head and neck cancer1 recruiting
• High blood pressure1 recruiting
• Kidney cancer1 recruiting
• Liver cirrhosis1 recruiting
• Mantle cell lymphoma1 recruiting
• Mesothelioma1 recruiting
• Metastatic breast cancer1 recruiting
• Myelodysplastic syndromes1 recruiting
• Parkinson disease1 recruiting
• Polycystic kidney disease1 recruiting
• Primary biliary cholangitis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Sarcoma1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection

  NCT06615921· Source

• Recruiting

  A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

  NCT06500884· Phase 2· Source

• Completed

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· Phase 3· Source

• Terminated

  IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack

  NCT06139328· Phase 2· Source

• Completed

  A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction

  NCT07304843· Phase 1/2· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Source

• Completed

  OptimiZation Of Lipid Lowering Therapies Using a Decision Support System In Patients With Acute Coronary Syndrome.

  NCT05844566· Source

• Completed

  Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

  NCT05291091· Phase 2· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Source

• Terminated

  A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults

  NCT04999202· Phase 1· Source

• Completed

  A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

  NCT04458831· Source

• Terminated

  A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

  NCT04271475· Phase 3· Source

• Completed

  Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients With Diabetes Mellitus Global

  NCT04236609· Source

• Completed

  Registry of Asthma Patients Initiating DUPIXENT®

  NCT04287621· Source

• Completed

  A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

  NCT04083976· Phase 2· Source

• Terminated

  Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis

  NCT03696290· Phase 4· Source

• Completed

  Benralizumab Exacerbation Study

  NCT04102800· Phase 4· Source

• Terminated

  PS101-mediated ACT With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin

  NCT04021277· Phase 1· Source

• Completed

  A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

  NCT03976362· Phase 3· Source

• Completed

  Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT

  NCT04173533· Phase 3· Source

• Completed

  A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

  NCT03782207· Source

• Completed

  EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110· Phase 3· Source

• Completed

  Study to Evaluate CCS1477 in Advanced Tumours

  NCT03568656· Phase 1/2· Source

• Completed

  A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

  NCT03274492· Phase 3· Source

• Completed

  Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

  NCT01938248· Phase 4· Source

• Completed

  Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer

  NCT03048942· Phase 2· Source

• Completed

  Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers

  NCT01597219· Phase 2· Source

Trial sites

• Freeman Hospital3 trials
• Freeman Hospital33 trials
• Freeman Hospital, Newcastle4 trials
• Freeman Hospital, Newcastle Upon Tyne2 trials
• Newcastle Freeman Hospital3 trials
• Freeman Hospital62 trials
• Freeman Hospital - Dept of Rheumatology1 trial
• Freeman Hospital - Investigational Site Number : 82600031 trial
• Freeman Hospital, Newcastle3 trials
• Freeman Hospital (Site 0444)1 trial
• Freeman Hospital (Site 0532)1 trial
• Freeman Hospital (Site 1205)1 trial
• Freeman Hospital (Site 3400)1 trial
• Newcastle Freeman Hospital6 trials
• Newcastle Freeman Hospital (Site 1902)1 trial
• Northern Centre for Cancer Care, Freeman Hospital,1 trial
• Sir Bobby Robson Cancer Trials Research Centre, The Northern Center for Cancer Care, Freeman Hospital1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Bronchiectasis21 works · 3 trials
• Aortic stenosis14 works · 5 trials